ORIC ORIC Pharmaceuticals, Inc.
Healthcare$8.54+2.64%ClosedMarket Cap: $884.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.11
P/S
0.00
EV/EBITDA
-5.73
DCF Value
$0.35
FCF Yield
-12.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-35.3%
ROA
-31.0%
ROIC
-35.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-39.6M | $-35.8M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-34.6M | $-30.5M | $— | — |
| FY null | $0.00 | -Infinity% | $-143.0M | $-129.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-36.7M | $-32.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-39.1M | $-36.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-32.7M | $-30.0M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-39.6M | $-36.3M | $— | — |
| FY null | $0.00 | -Infinity% | $-142.9M | $-127.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-38.3M | $-34.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-36.0M | $-32.0M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-29.0M | $-25.0M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-31.4M | $-28.3M | $-0.49 | — |